We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead Sciences has signed four more non-exclusive licensing agreements with generic drugmakers to make remdesivir available to COVID-19 patients in low-income countries. Read More
Hydroxychloroquine and chloroquine were dealt another blow as treatments for COVID-19 yesterday when the FDA revoked its Emergency Use Authorization (EUA) for the drugs — and warned that combining the antimalarials with Gilead Sciences’ remdesivir can decrease the antiviral activity of remdesivir. Read More
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance to provide up to 400 million doses of its COVID-19 vaccine at no profit starting by the end of the year. Read More